重组人血小板生成素联合地塞米松治疗原发免疫性血小板减少症疗效探讨.docVIP

重组人血小板生成素联合地塞米松治疗原发免疫性血小板减少症疗效探讨 　　【摘要】 目的 探讨重组人血小板生成素联合地塞米松治疗原发免疫性血小板减少症的临床疗效。方法 64例原发免疫性血小板减少症患者， 将其随机分成对照组和观察组， 每组32例。对照组患者使用地塞米松治疗， 观察组患者使用重组人血小板生成素联合地塞米松治疗。比较两组治疗效果。结果 治疗后， 观察组血小板计数为（132.8±65.6）×109/L， 高于对照组的（76.8±68.5）×109/L， 差异有统计学意义（P0.05）。结论 重组人血小板生成素联合地塞米松治疗原发免疫性血小板减少症疗效显著， 无明显副作用， 可在临床推广用。 　　【关键词】 重组人血小板生成素；地塞米松；原发免疫性血小板减少症；疗效 　　DOI：10.14163/j.cnki.11-5547/r.2017.09.045 　　Investigation of curative effect by recombinant human thrombopoietin combined with dexamethasone in the treatment of primary immune thrombocytopenia HU Xiao-ping. Shandong PKU Healthcare Luzhong Hospital， Zibo 255400， China 　　【Abstract】 Objective To investigate clinical effect by recombinant human thrombopoietin combined with dexamethasone in the treatment of primary immune thrombocytopenia. Methods A total of 64 patients with primary immune thrombocytopenia were randomly divided into control group and observation group， with 32 cases in each group. The control group received dexamethasone for treatment， and the observation group received recombinant human thrombopoietin combined with dexamethasone for treatment. Curative effects were compared between the two groups. Results After treatment， the observation group had higher blood platelet count as （132.8±65.6）×109/L than （76.8±68.5）×109/L in the control group， and their difference had statistical significance （P0.05）. Conclusion Combination of recombinant human thrombopoietin and dexamethasone shows excellent curative effect in treating primary immune thrombocytopenia， without obvious adverse reactions. This method is worth clinical promotion and application. 　　【Key words】 Recombinant human thrombopoietin； Dexamethasone； Primary immune thrombocytopenia； Curative effect 　　原?l免疫性血小板减少症是以循环血小板减少和出血风险增加为特征的血液系统疾病， 占出血性疾病的1/3， 有着较高的致死率[1]。正常生理条件下血小板减少时血小板生成素随之增加， 但该类患者的血小板生成素不会随之变化[2]， 无法形成弥补性机制。目前临床治疗血小板减少症的主要药物是糖皮质激素， 促血小板生成素近年也被应用到该病治疗当中， 本研究探讨重组人血小板生成素联合地塞米松治疗原发免疫性血小板减少症的疗效， 现报告如下。 　　1 资料与方法 　　1. 1 一般资料 选取2015年2月～2016年2月本院收治的64例